Biote (BTMD) Current Deferred Revenue (2021 - 2025)
Biote has reported Current Deferred Revenue over the past 5 years, most recently at $3.0 million for Q4 2025.
- Quarterly results put Current Deferred Revenue at $3.0 million for Q4 2025, up 1.89% from a year ago — trailing twelve months through Dec 2025 was $3.0 million (up 1.89% YoY), and the annual figure for FY2025 was $3.0 million, up 1.89%.
- Current Deferred Revenue for Q4 2025 was $3.0 million at Biote, down from $3.2 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for BTMD hit a ceiling of $3.2 million in Q3 2025 and a floor of $1.7 million in Q4 2021.
- Median Current Deferred Revenue over the past 5 years was $2.9 million (2024), compared with a mean of $2.6 million.
- Biggest five-year swings in Current Deferred Revenue: soared 52.77% in 2023 and later dropped 3.39% in 2025.
- Biote's Current Deferred Revenue stood at $1.7 million in 2021, then grew by 15.25% to $2.0 million in 2022, then soared by 52.77% to $3.0 million in 2023, then fell by 1.37% to $3.0 million in 2024, then increased by 1.89% to $3.0 million in 2025.
- The last three reported values for Current Deferred Revenue were $3.0 million (Q4 2025), $3.2 million (Q3 2025), and $3.1 million (Q2 2025) per Business Quant data.